MIM
ZYNE

MetLife Investment Management’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

MetLife Investment Management’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-11,100
Closed -$150K – 2415
2019
Q2 		$150K Buy
+11,100
New +$128K ﹤0.01% 2189

Other funds holding ZYNE

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return
ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MetLife Investment Management's ZYNE Position: Q3 2019 in Review

MetLife Investment Management sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q3 2019, closing a stake of 11,100 shares — an estimated $150K sold.

MetLife Investment Management first reported a position in ZYNE in Q2 2019 and held it in 1 quarter. The position peaked at $150K in Q2 2019. 84 funds tracked by Wall St. Rank hold ZYNE as of Q3 2019.

  • MetLife Investment Management reported no remaining Zynerba Pharmaceuticals, Inc position as of Q3 2019 after selling out during the quarter.
  • MetLife Investment Management sold 11,100 Zynerba Pharmaceuticals, Inc shares in Q3 2019, an estimated $150K.
  • MetLife Investment Management first reported a position in Zynerba Pharmaceuticals, Inc in Q2 2019 and held it in 1 quarter.
  • MetLife Investment Management's Zynerba Pharmaceuticals, Inc position peaked at $150K in Q2 2019.
  • 84 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q3 2019.

Based on MetLife Investment Management's 13F filing for Q3 2019, filed 14 Nov 2019.